Proteomics international Laboratories Ltd (PIQ.ASX).
Biotechnology: Diagnostics
About PIQ
Proteomics International Laboratories Ltd (PIQ.ASX) is a revenue generating medical technology company at the forefront of precision medicine and predictive diagnostics. In conjunction with Sonic Healthcare USA, PIQ is currently rolling out its world-first, predictive diagnostic test, PromarkerD, which can predict the onset of diabetic kidney disease (DKD) before clinical symptoms appear, up to four years in advance.
​
Proteomics International has several diagnostics in its pipeline, namely a world first blood test for Endometriosis (affects 1 in 9 women), and Oesophageal Cancer (1 in 20 cancer deaths). These diagnostics are in the final stages of validation and if successful present blockbuster opportunties.
Candour and PIQ
In a previous role Dirk and Alastair assisted PIQ’s IPO. We subsequently followed the Company closely and were formally engaged in 2018.
​
We have played a critical role in the transformation of PIQ, focusing the company’s messaging, successfully executing three capital raises, at successively higher prices, introducing supportive brokers & institutions (national & international) to the register.
These initiatives have resulted in a supportive shareholder base that has re-rated the company 4-6x. We continue to provide advice, preparing the company for key commercialisation milestones.
Candour Commentary
Recent Announcement Example
1 / Item Title
1 / Item Title